

Disclaimer

This presentation may contain forward looking statements that involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other companies, shifts in customer demands, customers and partners, changes in operating expenses, including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. You are cautioned not to place undue reliance on these presentation and the information contain therein, which are based on current view of management on future events.

Without prejudice to or derogating from the generality of the foregoing, no representation or assurance is given by Riverstone that this presentation contain all information that an investor may require. To the extent permitted by applicable law, Riverstone or its related persons (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) arising from the reliance or use of the information contain in this presentation.

Investors are advised to make their own independent evaluation from this presentation, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as the legal, business, financial, tax and other aspects as investors may regard as relevant.

Agenda






Results Overview

- Revenue increased 24.8% yoy from RM654.9 million for FY2016 to RM817.4 million for FY2017
- Net profit increased 7.4% yoy from RM120.4 million for FY2016 to RM129.3 million for FY2017
- Continues to generate positive operating free cash flow of RM145.7 million for FY2017
- Net cash position of **RM89.3 million**




Growing Revenues




* Annual figures may have some discrepancy due to rounding

Gross Profit & Gross Profit Margin



* Annual figures may have some discrepancy due to rounding

Net Profit & Net Profit Margin



RS

Positive Cash Flow Generation From Operating Activities



RM 'million


* Annual figures may have some discrepancy due to rounding

Robust Balance Sheet Strength

Year End 31 Dec	As at 31 Dec 2017 (RM'000)	As at 31 Dec 2016 (RM'000)
Net cash and cash equivalents	114,250	103,195
Total borrowings	25,000	0
Shareholders equity	634,295	554,508
Net assets (RM Sen per share) ¹	85.59	74.82
Return on equity ("ROE")	20.4% (FY2017)	21.7% (FY2016)

¹Based on 741.1 million shares in issue excluding treasury shares as at 31 December 2017 and 31 December 2016 respectively

Consistent Dividends since IPO



Dividends Declared (RM Sen/Share)~

~Adjusted for the 1:1 bonus shares

Dividend Payout Ratio	
FY2017	40.1%
FY2016	40.0%
FY2015	37.8%
FY2014	36.0%
FY2013	42.4%
FY2012	49.3%
FY2011	48.4%
FY2010	45.5%
FY2009	55.6%^
FY2008	45.2%
FY2007	45.0%
FY2006	28.0%

[^] including a special 1 sen tax-exempt dividend

Agenda







Phase 4 expansion is now completed with seven production lines fully commissioned, bringing the Group's total annual production capacity to 7.6 billion gloves

- Phase 5 expansion is now underway with an additional 1.4 billion pieces to ramp up total annual production capacity to 9.0 billion pieces by end FY2018
- Phase 6 expansion to add another 1.4 billion pieces by end FY2019 to 10.4 billion pieces in total annual production capacity
- Non-HDD markets for cleanroom gloves as well as US and Japan markets for both cleanroom and healthcare gloves continue to gain traction
- Continue to tap on fast-growing markets for healthcare gloves

Outlook

Key Challenges

Challenges	Actions
Competition	 Cleanroom: Continue to target new markets and customers Healthcare: Focus on customised and premium products
Increase in costs such as raw material, labor, and fuel	 Automation Improve productivity using Lean Six Sigma Reduce changeover time by installing an additional line

Investment Merits

Continues to be in expansion mode driven by growth in both cleanroom and healthcare gloves –

36.8% increase in production capacity by end 2019 to 10.4 billion pieces of gloves Resilient balance sheet with net cash position with continued ability to generate positive operating cash flow



Consistent dividend payout since listing

Committed management team









